Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

• Arne Christians,

  Affiliation Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany

  ⨯
• Christian Hartmann ,

  * E-mail: hartmann.christian@mh-hannover.de

  Affiliation Department of Neuropathology, Institute of Pathology, Hannover Medical School (MHH), Hannover, Germany

  ⨯
• Axel Benner,

  Affiliation Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany

  ⨯
• Jochen Meyer,

  Affiliation Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany

  ⨯
• Andreas von Deimling,

  Affiliations Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany, Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

  ⨯
• Michael Weller,

  Affiliations Department of Neurology, University Hospital Zurich, Zurich, Switzerland, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

  ⨯
• Wolfgang Wick,

  Affiliations Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany, Department of Neurooncology at the National Center for Tumour Diseases, Heidelberg University Hospital, Heidelberg, Germany, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

  ⨯
• Markus Weiler

  Affiliations Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany, Department of Neurooncology at the National Center for Tumour Diseases, Heidelberg University Hospital, Heidelberg, Germany, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

  ⨯